Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from Werewolf Therapeutics (HOWL).
Werewolf Therapeutics, Inc. revealed encouraging initial results from their ongoing Phase 1/1b clinical trial of WTX-124, showing potential in treating advanced solid tumors post-checkpoint inhibitor therapy. The data, presented at the ASCO Annual Meeting, indicated that WTX-124, both alone and combined with pembrolizumab, elicited tumor regression and was generally well-tolerated. The company has established a recommended dose for further study and is planning to discuss accelerated approval pathways for WTX-124, bolstered by additional positive observations in melanoma patients.
See more data about HOWL stock on TipRanks’ Stock Analysis page.
